shutterstock-163310765-3

Andy P / Shutterstock.com

30 May 2014Europe

Imanova: investing in know-how

Given the spiralling costs and ever-present risks associated with developing a new drug, pharmaceutical companies are always looking for ways to shorten the pathway from lab bench to clinic.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

'Nothing can stand in the way of our work': Ukraine resumes IP system

Taylor Wessing expands in Europe with Paris team

UPC orders 17-country ban on EOFlow's pumps in Insulet feud

AstraZeneca to appeal invalidated diabetes patent in generics dispute

Commercialising genomic tech in Nigeria

Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO

WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025